EUVIMEDEUVIMED entdecken
Crossref

PROGNOSTIC VALUE OF THE HALP SCORE IN METASTATIC UROTHELIAL CARCINOMA TREATED WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

Fatih Atalah, Akgün Karakök, Aydın Acarbay, İsmail Nazlı, Onur Alkan, Okan Aydın Aydın, Mehmet Beşiroğlu, Mahmut Gümüş

Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi · 14.08.2026 · 89 (3) · 163-168

DOI: 10.26650/iuitfd.1913645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, online erschienen am 14.08.2026. Verfasst von Fatih Atalah und 7 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Metastatic urothelial carcinoma (mUC) demonstrates substantial clinical heterogeneity, and outcomes may vary despite similar treatment approaches. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has emerged as a potential prognostic biomarker reflecting nutritional, inflammatory, and immune status. This study evaluated the prognostic significance of HALP in patients with mUC treated with first-line platinum-based chemotherapy.Materials and Methods: We retrospectively evaluated patients with metastatic or unresectable urothelial carcinoma who received first-line platinum-based chemotherapy at a single center between january 2015 and december 2023. HALP scores were calculated using baseline laboratory parameters obtained before treatment initiation. Patients were stratified according to the median HALP value. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS) was the secondary end point. Survival analyses were performed using the Kaplan – Meier and Cox regression methods.

Results

A total of 118 patients were included. The median HALP value was 24; 64 patients were classified as low HALP and 54 as high HALP. Patients with low HALP had significantly poorer outcomes. Median PFS was 4.90 months in the low HALP group and 7.67 months in the high HALP group. Median OS was 5.82 and 20.33 months, respectively (p

Zitieren

APA

Atalah, F., Karakök, A., Acarbay, A., Nazlı, İ., Alkan, O., Aydın, O. A., Beşiroğlu, M., & Gümüş, M. (2026). PROGNOSTIC VALUE OF THE HALP SCORE IN METASTATIC UROTHELIAL CARCINOMA TREATED WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY. Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 89(3), 163-168. https://doi.org/10.26650/iuitfd.1913645

Vancouver

Atalah F, Karakök A, Acarbay A, Nazlı İ, Alkan O, Aydın OA, et al. PROGNOSTIC VALUE OF THE HALP SCORE IN METASTATIC UROTHELIAL CARCINOMA TREATED WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY. Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi. 2026;89(3):163-168. doi:10.26650/iuitfd.1913645

BibTeX
@article{Atalah2026,
  author = {Atalah, Fatih and Karakök, Akgün and Acarbay, Aydın and Nazlı, İsmail and Alkan, Onur and Aydın, Okan Aydın and Beşiroğlu, Mehmet and Gümüş, Mahmut},
  title = {PROGNOSTIC VALUE OF THE HALP SCORE IN METASTATIC UROTHELIAL CARCINOMA TREATED WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY},
  journal = {Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi},
  year = {2026},
  volume = {89},
  number = {3},
  pages = {163--168},
  doi = {10.26650/iuitfd.1913645}
}
Kostenlos starten →